MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 110

Biopharma Pharma 110

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. asked panel chair Ipsita Smolinski, MD of consultancy Capitol Street.

FDA 52

FDA Prescription Medicine Biopharma 52

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients. Key acquisitions by U.S. healthcare organizations Company Founded Type No.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

There are two ways telehealth waivers can be extended through 2025 – via The Centers for Medicare & Medicaid Rule and legislatively through 2026 via H.R. Other healthcare topics to watch: Telehealth About a dozen federal telehealth waivers put in place during the Covid pandemic are set to expire Dec.

Healthcare 52

Healthcare Healthcare Government Insurance 52